US Pharma MarketingFueled by M&A and partnerships, biotech is poised for continued growth: EY
Ernst & Young is projecting biotech revenues will grow by at least 12% in 2026, recording growth for the third straight year as the industry continues its upswing. Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug…
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well.
Source: FierceBiotech